File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy

TitleThe long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy
Authors
KeywordsChronic epilepsy
Gabapentin
Lamotrigine
Pharmacoepidemiology
Vigabatrin
Issue Date1999
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/
Citation
Epilepsia, 1999, v. 40 n. 10, p. 1439-1445 How to Cite?
AbstractPurpose: To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation. To assess the likelihood of seizure freedom, seizure-related injury/hospital admission and mortality after these drags were commenced. Methods: This was a retrospective case- records survey in five tertiary referral epilepsy centres in the U.K. The retention times on treatment (from initiation to discontinuation) for the different antiepileptic drugs (AEDs) were compared by using Kaplan-Meier survival analysis and Cox regression. Incidences of seizure freedom and seizure-related injury/hospital admissions and standardised mortality ratios were calculated. Results: There were 1,375 patients with chronic epilepsy included; 361 were taking GBP, 1,050 LTG, and 713 VGB. The retention of GBP, LTG, or VGB was <40% at 6 years. Fewer than 4% of patients become seizure free while taking one of the drugs. There was no reduction in mortality or seizure-related injury/admission. Conclusions: The impact of these new AEDs on chronic epilepsy can be described only as modest. This view may be revised, however, as more experience is gained with new drugs in previously untreated patients.
Persistent Identifierhttp://hdl.handle.net/10722/132921
ISSN
2015 Impact Factor: 4.706
2015 SCImago Journal Rankings: 2.579
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, ICKen_HK
dc.contributor.authorChadwick, DWen_HK
dc.contributor.authorFenwick, PBCen_HK
dc.contributor.authorMawer, GEen_HK
dc.contributor.authorSander, JWASen_HK
dc.date.accessioned2011-04-04T07:58:00Z-
dc.date.available2011-04-04T07:58:00Z-
dc.date.issued1999en_HK
dc.identifier.citationEpilepsia, 1999, v. 40 n. 10, p. 1439-1445en_HK
dc.identifier.issn0013-9580en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132921-
dc.description.abstractPurpose: To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation. To assess the likelihood of seizure freedom, seizure-related injury/hospital admission and mortality after these drags were commenced. Methods: This was a retrospective case- records survey in five tertiary referral epilepsy centres in the U.K. The retention times on treatment (from initiation to discontinuation) for the different antiepileptic drugs (AEDs) were compared by using Kaplan-Meier survival analysis and Cox regression. Incidences of seizure freedom and seizure-related injury/hospital admissions and standardised mortality ratios were calculated. Results: There were 1,375 patients with chronic epilepsy included; 361 were taking GBP, 1,050 LTG, and 713 VGB. The retention of GBP, LTG, or VGB was <40% at 6 years. Fewer than 4% of patients become seizure free while taking one of the drugs. There was no reduction in mortality or seizure-related injury/admission. Conclusions: The impact of these new AEDs on chronic epilepsy can be described only as modest. This view may be revised, however, as more experience is gained with new drugs in previously untreated patients.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.epilepsia.com/en_HK
dc.relation.ispartofEpilepsiaen_HK
dc.subjectChronic epilepsyen_HK
dc.subjectGabapentinen_HK
dc.subjectLamotrigineen_HK
dc.subjectPharmacoepidemiologyen_HK
dc.subjectVigabatrinen_HK
dc.titleThe long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsyen_HK
dc.typeArticleen_HK
dc.identifier.emailWong, ICK: wongick@hku.hken_HK
dc.identifier.authorityWong, ICK=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1528-1157.1999.tb02017.xen_HK
dc.identifier.pmid10528941-
dc.identifier.scopuseid_2-s2.0-0032841402en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0032841402&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume40en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1439en_HK
dc.identifier.epage1445en_HK
dc.identifier.isiWOS:000082947700014-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridWong, ICK=7102513915en_HK
dc.identifier.scopusauthoridChadwick, DW=12777302200en_HK
dc.identifier.scopusauthoridFenwick, PBC=7006226182en_HK
dc.identifier.scopusauthoridMawer, GE=7004053826en_HK
dc.identifier.scopusauthoridSander, JWAS=7202898360en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats